Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Efficacy of rifaximin among non-constipated irritable bowel syndrome patients with or without small intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial

Title: Efficacy of rifaximin among non-constipated irritable bowel syndrome patients with or without small intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial
Authors: Podder, Subrata; Masudur Rahman, M.; Hossain, Mohammad Iqbal; Datta, Raj; Alam, Jane; Golam Kibria, M.
Source: International Journal of Research in Medical Sciences; Vol. 12 No. 4 (2024): April 2024; 1056-1064 ; 2320-6012 ; 2320-6071
Publisher Information: Medip Academy
Publication Year: 2024
Subject Terms: Irritable bowel syndrome; Rifaximin; Gastrointestinal disorder; Dysbiosis; Antibiotic therapy
Description: Background: IBS is a functional gastrointestinal disorder marked by abdominal pain and changes in stool frequency or form. Recent studies indicate a link between IBS, especially the diarrhea-predominant subtype, and small intestinal bacterial overgrowth. This study aimed to evaluate symptom resolution among IBS patients with or without SIBO on rifaximin treatment as compared with placebo. Methods: A double-blind, placebo-controlled, randomized clinical trial took place at the Department of Gastroenterology, Dhaka Medical College and Hospital, from January to December 2019. In the study 104 non-constipated IBS patients were assessed for SIBO using gut aspirate culture. Those with SIBO (≥105 CFU/ml) and those without were randomly assigned (computer-generated) to receive either 1500 mg/day of rifaximin for 14 days or a placebo. Results: Among 104 non-constipated IBS patients, 39% had SIBO, with IBS-D patients more associated (83% vs. 60%). Rifaximin significantly improved symptoms in the SIBO group at 4 and 16 weeks (90% vs. 20%, p
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: https://www.msjonline.org/index.php/ijrms/article/view/13175/8532; https://www.msjonline.org/index.php/ijrms/article/view/13175
DOI: 10.18203/2320-6012.ijrms20240825
Availability: https://www.msjonline.org/index.php/ijrms/article/view/13175; https://doi.org/10.18203/2320-6012.ijrms20240825
Rights: Copyright (c) 2024 International Journal of Research in Medical Sciences
Accession Number: edsbas.23EB343A
Database: BASE